Recent Updates
Recently added Catalysts
TVTX Positive Sentiment

Jula Inrig Recognized in Endpoints News’ Women in Biopharma R&D, 2024

Wednesday, October 9, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Jula Inrig, M.D., the chief medical officer at Travere, has been recognized in Endpoints News' 2024 Women Leaders in R&D. This annual recognition honors women who are making significant contributions and breaking boundaries in the field of Biopharma research and development.
Price reaction · baseline $17.59 (2024-10-09 close) · hit after-hours · 1 other TVTX headline(s) in the window, move may be shared
day 0 close · peak
-2.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Jula Inrig recognized for her leadership in Biopharma R&D.
  • Celebration of women's contributions to the industry.
  • Highlighting advancements and boundary-breaking achievements.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+79%
120-day peak, hindsight
Typical move
4.7%
average across 9 past catalysts
Lead asset
sparsentan
Phase 3 · Immunoglobulin A Nephropathy

Full Press Release Details

Wednesday, October 9, 2024 — Jula Inrig, M.D., chief medical officer at Travere, was named to Endpoints News 2024 Women Leaders in R&D. Each year, Endpoints News celebrates leading women who continue to break boundaries in Biopharma R&D. Read the full article at Endpoints News .

Frequently Asked Questions

Who is Jula Inrig?

Jula Inrig, M.D., is the chief medical officer at Travere.

What recognition did Jula Inrig receive?

She was named to Endpoints News' 2024 Women Leaders in R&D.

What does the Endpoints News recognition celebrate?

It celebrates women who break boundaries in Biopharma R&D.

When was the recognition announced?

The announcement was made on October 9, 2024.

ShareAdd on Google
Tags: TVTX Viatris Investor Conferences Healthcare Jula Inrig Travere Endpoints News Women in Biopharma R&D
Last updated: Oct 9, 2024

Biotech snapshot

Cash runway
$489M liquidity · $0M/mo burn
Low dilution risk
Lead asset
sparsentanPhase 3
Immunoglobulin A Nephropathy →

Catalyst track record

+79%
best trade around TVTX's most recent catalyst

Peak hindsight return over a 120-day window, across 9 tracked FDA/PDUFA catalysts for TVTX.

See every catalyst's timing & PoA →